# Wefunder

于2026年为多家公司主办实时Reg CF募资活动，包括Mahzi Therapeutics（针对皮特-霍普金斯综合征及相关罕见神经发育障碍的基因疗法）及Eliaz Therapeutics（其通过去除半乳糖凝集素-3来针对脓毒症的血浆置换设备XGal-3）。

Source: https://cn.bioecon.ru/companies/wefunder/
Updated: 2026-07-04

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 此前从风险投资机构累计募集$6000万 | https://biobase.whitefordresearch.com/companies/mahzi-therapeutics, https://kingscrowd.com/mahzi-therapeutics-on-wefunder-2026/, https://thenyledger.com/business/rare-disease-families-can-now-invest-in-biotech-gene-therapy/ |
| 融资 | 累计获得California Institute for Regenerative Medicine（CIRM）$1600万拨款 | https://biobase.whitefordresearch.com/companies/mahzi-therapeutics, https://kingscrowd.com/mahzi-therapeutics-on-wefunder-2026/, https://thenyledger.com/business/rare-disease-families-can-now-invest-in-biotech-gene-therapy/ |
| 融资 | 2026年在Wefunder平台的Reg CF众筹发行，目标金额$50,000，最高$1.2 million | http://biobase.whitefordresearch.com/companies/mahzi-therapeutics, https://biobase.whitefordresearch.com/companies/mahzi-therapeutics, https://kingscrowd.com/mahzi-therapeutics-on-wefunder-2026/, https://wefunder.com/mahzi.therapeutics |
| 员工人数 | 员工14至17人 | https://kingscrowd.com/mahzi-therapeutics-on-wefunder-2026/ |
| 营收 | 截至2025财年为$0 | https://kingscrowd.com/mahzi-therapeutics-on-wefunder-2026/ |
| 监管批准 | MZ-1866 获得 FDA 孤儿药资格、快速通道认定及罕见儿科疾病认定 | https://www.biopharminternational.com/view/fda-grants-rare-pediatric-disease-designation-to-mahzi-s-aav9-gene-therapy-mz-1866-for-pitt-hopkins-syndrome, https://www.prnewswire.com/news-releases/mahzi-therapeutics-announces-fda-rare-pediatric-disease-designation-for-mz-1866-investigational-therapy-for-pitt-hopkins-syndrome-302857468.html |

独立来源: biobase.whitefordresearch.com, biopharminternational.com, kingscrowd.com, prnewswire.com, thenyledger.com

## 技术

- [生物技术众筹与散户投资](https://cn.bioecon.ru/technology/crowdfunding-retail-investment-biotech/)